MedTrace Logo

E-Five Registry: A World-Wide Registry With The Endeavor Zotarolimus Eluting Coronary Stent

NCT00623441 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8314

Last updated 2015-11-23

Study results available
· View outcomes & findings →

Summary

The safety and efficacy of the Endeavor(TM) ABT-578 Eluting Coronary Stent System has been assessed in a series of studies. The stent is coated with a proprietary drug compound that is designed to reduce restenosis.

This prospective multi-center study has been initiated:

* To document the acute and mid-term safety and overall clinical performance of the stent system in a "real world" patient population requiring stent implantation.
* To assess the event rate in patient subgroups with specific clinical indications and/or vessel or lesion characteristics.

Conditions

Interventions

DEVICE

Endeavor Zotarolimus Eluting Coronary Stent

Drug eluting stent

Sponsors & Collaborators

  • Medtronic Cardiac Rhythm and Heart Failure

    lead INDUSTRY

Principal Investigators

  • Ian T Meredith, MD · Monash Medical Centre, Melbourne, Australia

  • Chaim Lotan, MD · Hadassah University Hospital, Jerusalem, Israel

  • Martin T Rothman, MD · London Chest Hospital, London, United Kingdom

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2007-11-30
Completion
2009-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00623441 on ClinicalTrials.gov